Stock Events

Stock Events

BioMark Diagnostics 

C$0.4500
2
-C$0.02-4.26%Tuesday 18:44

Statistics

Day High
0.45
Day Low
0.45
52W High
0.64
52W Low
0.32
Volume
2,000
Avg. Volume
5,019
Mkt Cap
47.92M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-2,461.67%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
60,000Revenue
-1.48MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap23.99B
Guardant Health focuses on liquid biopsies and cancer diagnostics, directly competing in BioMark's market of early cancer detection.
Fulgent Genetics
FLGT
Mkt Cap567.37M
Fulgent Genetics offers extensive genetic testing, which is crucial for personalized cancer therapies, overlapping with BioMark's diagnostic solutions.
Illumina
ILMN
Mkt Cap35.63B
Illumina provides genomic sequencing solutions that are foundational to cancer research and diagnostics, impacting the same market as BioMark.
Qiagen NV
QGEN
Mkt Cap10.37B
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences offers sequencing systems that aid in understanding cancer genetics, competing in the broader diagnostics market.
Bionano Genomics
BNGO
Mkt Cap16.07M
Bionano Genomics focuses on genomic analysis, including cancer research, which aligns with BioMark's focus on diagnostic solutions.
Myriad Genetics
MYGN
Mkt Cap607.38M
Myriad Genetics specializes in molecular diagnostic tests that include cancer screenings, directly competing with BioMark's offerings.

About

BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Show More
CEO
Rashid Ahmed Maula Bux
Employees
9
Country
Canada
ISIN
CA09073K1084
WKN
000A12EKB

Listings

STU
DE
20B.STU
OTC Link
US
BMKDF
F
DE
20B.F
CN
CA
BUX.CN

0 Comments

Share your thoughts

FAQs

What is BioMark Diagnostics stock price today?▼
The current price of BUX.CN is C$0.45 CAD — it has decreased by -4.26% in the past 24 hours. Watch BioMark Diagnostics stock price performance more closely on the chart.
What is BioMark Diagnostics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Canadian Securities Exchange exchange BioMark Diagnostics stocks are traded under the ticker BUX.CN.
Is BioMark Diagnostics stock price growing?▼
BUX.CN stock has fallen by -4.26% compared to the previous week, the month change is a -19.64% fall, over the last year BioMark Diagnostics has showed a +30.43% increase.
What is BioMark Diagnostics market cap?▼
Today BioMark Diagnostics has the market capitalization of 47.92M
What is BioMark Diagnostics revenue for the last year?▼
BioMark Diagnostics revenue for the last year amounts to 60,000 CAD.
What is BioMark Diagnostics net income for the last year?▼
BUX.CN net income for the last year is -1.48M CAD.
How many employees does BioMark Diagnostics have?▼
As of November 4, 2026, the company has 9 employees.
In which sector is BioMark Diagnostics located?▼
BioMark Diagnostics operates in the Health & Wellness sector.
When did BioMark Diagnostics complete a stock split?▼
BioMark Diagnostics has not had any recent stock splits.
Where is BioMark Diagnostics headquartered?▼
BioMark Diagnostics is headquartered in Richmond, Canada.